2 unknown, 1 completed, 1 terminated. 1 Early Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Rabies Virus Infection: new trials by email Literature Review of Rabies Virus Infection trials Research Report on Rabies Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg, Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg, Rabies Human Immunoglobulin (HRIG) - Rabies Virus Infection | Phase 2 | Unknown | Changchun BCHT Biotechnology Co. | 120 | 2024-07-31 | 2024-08-12 |
| Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1 Natural full human monoclonal antibody CBB 1 injection, Rabies Human Immunoglobulin (HRIG), Natural full human monoclonal antibody CBB 1 injection placebo - Rabies Virus Infection | Early Phase 1 | Unknown | Changchun BCHT Biotechnology Co. | 152 | 2023-04-30 | 2023-04-27 |
| Survey of Human Rabies Immune Globulin Safety in Children Human rabies immune globulin 300 IU/mL - Rabies, Rabies Human | Terminated | The Methodist Hospital Research Institute | 35 | 2023-02-22 | 2025-11-13 | |
| Improving Adherence to Rabies PEP Guideline Recommendations Rabies PEP quality improvement bundle - Rabies, Rabies Human | Not applicable | Completed | The Methodist Hospital Research Institute | 70 | 2019-12-29 | 2021-09-05 |
Rabies (4)
Infections (4) · Mononegavirales Infections (4) · RNA Virus Infections (4) · Rhabdoviridae Infections (4) · Virus Diseases (4)
Changchun BCHT Biotechnology Co. (2) · The Methodist Hospital Research Institute (2)
China (2) · United States (2)
Joshua Swan, PharmD, MPH (1) · Michael Sirimaturos, PharmD (1)